Literature DB >> 19682280

Identification of direct transcriptional targets of (V600E)BRAF/MEK signalling in melanoma.

Leisl M Packer1, Philip East, Jorge S Reis-Filho, Richard Marais.   

Abstract

Oncogenic mutations in BRAF are common in melanoma and drive constitutive activation of the MEK/ERK pathway. To elucidate the transcriptional events downstream of (V600E)BRAF/MEK signalling we performed gene expression profiling of A375 melanoma cells treated with potent and selective inhibitors of (V600E)BRAF and MEK (PLX4720 and PD184352 respectively). Using a stringent Bayesian approach, we identified 69 transcripts that appear to be direct transcriptional targets of this pathway and whose expression changed after 6 h of pathway inhibition. We also identified several additional genes whose expression changed after 24 h of pathway inhibition and which are likely to be indirect transcriptional targets of the pathway. Several of these were confirmed by demonstrating their expression to be similarly regulated when BRAF was depleted using RNA interference, and by using qRT-PCR in other BRAF mutated melanoma lines. Many of these genes are transcription factors and feedback inhibitors of the ERK pathway and are also regulated by MEK signalling in NRAS mutant cells. This study provides a basis for understanding the molecular processes that are regulated by (V600E)BRAF/MEK signalling in melanoma cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19682280     DOI: 10.1111/j.1755-148X.2009.00618.x

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN: 1755-1471            Impact factor:   4.693


  37 in total

Review 1.  Genetic alterations of PTEN in human melanoma.

Authors:  Almass-Houd Aguissa-Touré; Gang Li
Journal:  Cell Mol Life Sci       Date:  2011-11-11       Impact factor: 9.261

2.  Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells.

Authors:  Yongping Shao; Andrew E Aplin
Journal:  Cancer Res       Date:  2010-07-20       Impact factor: 12.701

3.  What are the therapeutic implications of increased collagen expression in melanoma cells treated with vemurafenib?

Authors:  Constance E Brinckerhoff
Journal:  Melanoma Manag       Date:  2016-02-18

4.  Ring finger protein 149 is an E3 ubiquitin ligase active on wild-type v-Raf murine sarcoma viral oncogene homolog B1 (BRAF).

Authors:  Seung-Woo Hong; Dong-Hoon Jin; Jae-Sik Shin; Jai-Hee Moon; Young-Soon Na; Kyung-Ah Jung; Seung-Mi Kim; Jin Cheon Kim; Kyu-Pyo Kim; Yong Sang Hong; Jae-Lyun Lee; Eun Kyung Choi; Jung Shin Lee; Tae Won Kim
Journal:  J Biol Chem       Date:  2012-05-24       Impact factor: 5.157

Review 5.  Targeting BRAF in advanced melanoma: a first step toward manageable disease.

Authors:  Adina Vultur; Jessie Villanueva; Meenhard Herlyn
Journal:  Clin Cancer Res       Date:  2011-03-29       Impact factor: 12.531

6.  Late intervention with anti-BRAF(V600E) therapy induces tumor regression in an orthotopic mouse model of human anaplastic thyroid cancer.

Authors:  Matthew A Nehs; Carmelo Nucera; Sushruta S Nagarkatti; Peter M Sadow; Dieter Morales-Garcia; Richard A Hodin; Sareh Parangi
Journal:  Endocrinology       Date:  2011-12-27       Impact factor: 4.736

7.  The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway.

Authors:  Catherine Andreadi; Lai-Kay Cheung; Susan Giblett; Bipin Patel; Hong Jin; Kathryn Mercer; Tamihiro Kamata; Pearl Lee; Alexander Williams; Martin McMahon; Richard Marais; Catrin Pritchard
Journal:  Genes Dev       Date:  2012-08-14       Impact factor: 11.361

8.  Sildenafil use and increased risk of incident melanoma in US men: a prospective cohort study.

Authors:  Wen-Qing Li; Abrar A Qureshi; Kathleen C Robinson; Jiali Han
Journal:  JAMA Intern Med       Date:  2014-06       Impact factor: 21.873

9.  Rapid Remodeling of Invadosomes by Gi-coupled Receptors: DISSECTING THE ROLE OF Rho GTPases.

Authors:  Katarzyna M Kedziora; Daniela Leyton-Puig; Elisabetta Argenzio; Anja J Boumeester; Bram van Butselaar; Taofei Yin; Yi I Wu; Frank N van Leeuwen; Metello Innocenti; Kees Jalink; Wouter H Moolenaar
Journal:  J Biol Chem       Date:  2016-01-06       Impact factor: 5.157

10.  Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma.

Authors:  Lawrence N Kwong; James C Costello; Huiyun Liu; Shan Jiang; Timothy L Helms; Aliete E Langsdorf; David Jakubosky; Giannicola Genovese; Florian L Muller; Joseph H Jeong; Ryan P Bender; Gerald C Chu; Keith T Flaherty; Jennifer A Wargo; James J Collins; Lynda Chin
Journal:  Nat Med       Date:  2012-09-16       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.